Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor

Apolipoprotein B100 (apoB100) is a structural component of low-density lipoprotein (LDL) and a ligand for the LDL receptor (LDLR) 1 . Mutations in apoB100 or in LDLR cause familial hypercholesterolaemia, an autosomal dominant disease that is characterized by a marked increase in LDL cholesterol (LDL...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature (London) Jg. 638; H. 8051; S. 829 - 835
Hauptverfasser:	Reimund, Mart, Dearborn, Altaira D., Graziano, Giorgio, Lei, Haotian, Ciancone, Anthony M., Kumar, Ashish, Holewinski, Ronald, Neufeld, Edward B., O’Reilly, Francis J., Remaley, Alan T., Marcotrigiano, Joseph
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 20.02.2025 Nature Publishing Group
Schlagworte:	101/28 631/443/592/75 631/535/1258/1259 Apolipoprotein B-100 - chemistry Apolipoprotein B-100 - genetics Apolipoprotein B-100 - metabolism Apolipoprotein B-100 - ultrastructure Apolipoproteins Binding Binding Sites Cardiovascular disease Cardiovascular diseases Cholesterol Cryoelectron Microscopy Density Electron microscopy Epidermal growth factor Health risks Humanities and Social Sciences Humans Hypercholesterolemia Interfaces Ligands Lipids Lipoproteins Lipoproteins, LDL - chemistry Lipoproteins, LDL - metabolism Lipoproteins, LDL - ultrastructure Low density lipoprotein Low density lipoprotein receptors Microscopy Models, Molecular multidisciplinary Mutation Nanobodies Pathogenesis Protein Binding Protein Domains Receptor density Receptors Receptors, LDL - chemistry Receptors, LDL - genetics Receptors, LDL - metabolism Receptors, LDL - ultrastructure Science Science (multidisciplinary) Single-Domain Antibodies - chemistry Single-Domain Antibodies - metabolism Single-Domain Antibodies - ultrastructure
ISSN:	0028-0836, 1476-4687, 1476-4687
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!